Supplementary Figure 1: Heat map of recurrent mutations in patients with histiocytic neoplasms based on results from prior sequencing studies [(8)*, (9), (11), (12), (13), (14), (15), (16), (17)*, (18)*, (19), (20), (23), (24), (25)**]. Each column represents a single patient. The type of histiocytic neoplasm (LCH, ECD, JXG, RDD, HS, and ICH) is represented in the first row. The gene that is mutated or involved in a fusion is represented in the subsequent rows. As shown, *ARAF*, *MAP3K1*, and *PIK3CA* mutations have been shown to co-occur with *BRAF* V600E mutations in histiocytoses [(8)*, (19), (20), (23)]. Also, *ARAF* mutations have been shown to co-occur with *NRAS* mutations in JXG [(8)*], and an activating *BRAF* F595L mutation has been described to co-occur with an activating *HRAS* mutation in histiocytic sarcoma [(15)].